Table 6: Viral suppression among persons aged ≥13 years living with HIV in 17 US jurisdictions by race, sex and selected characteristics, 2012-2015

Characteristic Viral Suppression
2012 2013 2014 2015 Trend in 2012-2015
(N=440,375) (N=451,885) (N=464,461) (N=477,928) EAPC 95% CI P-value
No. (%) No. (%) No. (%) No. (%) Lower Upper
Black Male
      Age group at diagnosis
      13-24 2,513 36.6 2,967 41.5 3,348 46.4 3,436 48.3 9.8 8.0 11.5 <.001
      25-34 7,340 40.3 8,697 44.9 10,253 48.3 11,560 49.7 7.0 6.0 8.0 <.001
      35-44 11,105 45.2 11,413 48.6 11,852 51.5 11,666 51.4 4.5 3.7 5.4 <.001
      45-54 18,904 48.8 20,028 51.9 20,868 53.9 20,553 53.7 3.2 2.6 3.9 <.001
      55+ 12,388 49.3 14,368 51.3 16,204 52.6 17,856 52.8 2.3 1.5 3.0 <.001
      Stage at diagnosis
      HIV infection stage 3(AIDS) 14,476 51.0 15,418 53.6 16,244 55.4 16,603 55.7 3.0 2.3 3.7 <.001
      Not known to be HIV infection stage 3 37,774 44.4 42,055 47.9 46,281 50.5 48,468 50.8 4.6 4.1 5.0 <.001
      Transmission Categoryc
      Male-to-male sexual contact 30,899 47.3 34,892 50.9 38,904 53.5 41,682 54.2 4.5 4.1 5.0 <.001
      Injection drug use 8,850 41.0 9,267 43.7 9,451 45.2 9,040 44.0 2.5 1.5 3.4 <.001
      Male-to-male sexual contact and injection drug use 4,202 47.4 4,394 50.6 4,651 53.8 4,513 52.4 3.6 2.3 5.0 <.001
      Heterosexual contactd 8,182 46.8 8,800 49.2 9,379 51.0 9,699 51.6 3.3 2.4 4.3 <.001
      Othere 117 40.2 120 40.6 140 46.3 137 44.3 4.3 -3.5 12.7 .288
Black Female
      Age group at diagnosis
      13-24 683 32.3 741 37.9 758 40.6 778 45.7 11.7 8.1 15.4 <.001
      25-34 3,544 38.3 3,727 41.9 3,780 43.8 3,901 46.2 6.2 4.7 7.8 <.001
      35-44 7,537 44.9 7,909 47.8 8,228 50.6 8,352 51.8 5.0 4.0 6.0 <.001
      45-54 9,887 51.7 10,560 54.3 11,190 56.3 11,487 56.9 3.2 2.4 4.1 <.001
      55+ 6,157 55.1 7,398 58.7 8,470 60.3 9,489 60.6 3.0 2.0 4.1 <.001
      Stage at diagnosis
      HIV infection stage 3(AIDS) 6,984 53.7 7,471 56.7 7,823 58.4 8,140 59.5 3.4 2.4 4.4 <.001
      Not known to be HIV infection stage 3 20,824 45.8 22,864 49.4 24,603 52.0 25,867 53.4 5.2 4.6 5.8 <.001
      Transmission Categoryc
      Injection drug use 6,693 45.1 7,062 48.3 7,318 50.6 7,323 51.1 4.3 3.2 5.4 <.001
      Heterosexual contactd 20,969 48.4 23,108 51.9 24,930 54.3 26,503 55.9 4.8 4.2 5.4 <.001
      Othere 146 49.1 166 54.2 178 57.3 182 57.4 5.2 -1.7 12.6 .140
Hispanic/Latino Male
      Age group at diagnosis
      13-24 1,389 45.1 1,677 51.0 1,904 57.5 2,044 59.4 9.7 7.4 12.0 .001
      25-34 7,437 49.0 8,360 52.6 9,452 56.4 10,111 58.0 5.8 4.9 6.8 <.001
      35-44 13,552 52.9 13,819 54.9 14,225 57.4 14,231 57.5 3.0 2.2 3.7 <.001
      45-54 16,193 56.1 17,525 57.8 18,893 59.8 19,501 59.8 2.2 1.6 2.9 <.001
      55+ 8,258 55.4 9,455 56.5 10,909 58.5 12,037 57.9 1.6 0.8 2.5 <.001
      Stage at diagnosis
      HIV infection stage 3(AIDS) 13,921 53.4 14,727 54.9 15,701 57.0 16,111 56.9 2.3 1.6 3.0 <.001
      Not known to be HIV infection stage 3 32,908 53.4 36,109 55.9 39,682 58.8 41,813 59.1 3.5 3.1 4.0 <.001
      Transmission Categoryc
      Male-to-male sexual contact 34,225 56.1 37,902 58.6 41,716 61.2 44,306 61.6 3.2 2.8 3.7 <.001
      Injection drug use 5,439 42.6 5,462 43.1 5,662 44.9 5,526 44.1 1.5 0.3 2.7 .012
      Male-to-male sexual contact and injection drug use 3,520 52.4 3,667 54.2 3,854 56.9 3,835 56.5 2.8 1.3 4.2 <.001
      Heterosexual contactd 3,533 51.0 3,691 51.9 4,033 54.9 4,137 54.8 2.8 1.3 4.2 <.001
      Othere 112 53.6 115 54.4 119 57.3 120 58.3 3.1 -4.9 11.9 .460
Hispanic/Latino Female
      Age group at diagnosis
      13-24 246 42.6 239 44.2 243 48.5 234 49.4 5.5 -0.3 11.7 .061
      25-34 1,409 45.7 1,449 49.3 1,452 51.5 1,450 52.8 4.9 2.5 7.3 <.001
      35-44 3,117 52.6 3,153 54.0 3,248 57.0 3,197 58.0 3.5 1.9 5.2 <.001
      45-54 4,282 58.2 4,454 59.7 4,717 62.1 4,828 63.3 3.0 1.7 4.3 <.001
      55+ 2,849 61.9 3,285 64.1 3,717 65.4 4,154 65.2 1.7 0.2 3.2 .028
      Stage at diagnosis
      HIV infection stage 3(AIDS) 2,990 57.5 3,121 59.3 3,298 61.8 3,410 62.5 2.9 1.4 4.6 <.001
      Not known to be HIV infection stage 3 8,913 54.5 9,459 56.8 10,079 59.4 10,453 60.5 3.6 2.7 4.5 <.001
      Transmission Categoryc
      Injection drug use 3,037 51.2 3,099 52.9 3,194 54.9 3,260 56.5 3.4 1.8 5.0 <.001
      Heterosexual contactd 8,792 56.8 9,406 59.1 10,105 61.8 10,525 62.6 3.4 2.5 4.3 <.001
      Othere 74 53.8 75 55.2 78 57.6 78 56.9 2.1 -7.6 12.9 .679
White Male
      Age group at diagnosis
      13-24 803 50.5 931 57.8 966 59.3 1,060 63.7 7.3 4.3 10.4 <.001
      25-34 5,580 54.9 6,420 60.6 6,911 63.4 7,152 63.6 4.8 3.7 6.0 <.001
      35-44 14,844 59.5 14,568 62.6 14,139 64.8 13,338 64.7 2.9 2.2 3.7 <.001
      45-54 30,648 63.4 32,129 66.2 32,669 68.1 32,065 67.9 2.4 1.9 2.9 <.001
      55+ 20,434 64.3 23,543 66.8 26,875 69.4 29,606 69.3 2.5 2.0 3.1 <.001
      Stage at diagnosis
      HIV infection stage 3(AIDS) 17,032 62.7 18,019 65.3 18,688 67.2 18,950 67.3 2.4 1.7 3.1 <.001
      Not known to be HIV infection stage 3 55,277 61.6 59,572 65.0 62,872 67.4 64,271 67.4 3.0 2.7 3.4 <.001
      Transmission Categoryc
      Male-to-male sexual contact 60,780 63.3 65,462 66.5 68,995 68.9 70,553 68.8 2.8 2.5 3.2 <.001
      Injection drug use 3,024 47.8 3,171 50.3 3,252 52.0 3,210 51.3 2.5 0.9 4.1 .002
      Male-to-male sexual contact and injection drug use 6,244 58.9 6,541 61.6 6,810 64.4 6,877 65.1 3.5 2.4 4.6 <.001
      Heterosexual contactd 1,932 58.9 2,083 61.7 2,172 62.5 2,238 63.1 2.2 0.2 4.1 .028
      Othere 329 59.4 334 61.9 332 63.7 343 66.1 3.6 -1.3 8.6 .151
White Female
      Age group at diagnosis
      13-24 147 39.4 148 42.2 132 44.4 127 46.0 5.3 -2.2 13.5 .172
      25-34 907 44.9 921 47.0 965 50.8 926 49.9 4.0 1.1 7.1 .007
      35-44 1,925 48.9 1,978 52.1 1,952 53.6 1,907 53.9 3.2 1.2 5.3 .002
      45-54 2,926 55.9 3,116 58.5 3,265 60.3 3,274 60.6 2.7 1.1 4.3 <.001
      55+ 1,864 59.4 2,167 62.1 2,482 64.1 2,768 64.1 2.5 0.7 4.4 .007
      Stage at diagnosis
      HIV infection stage 3(AIDS) 1,786 57.5 1,914 60.5 2,017 62.6 2,047 63.1 3.1 1.1 5.2 .003
      Not known to be HIV infection stage 3 5,983 51.6 6,416 54.6 6,779 56.9 6,955 57.3 3.6 2.4 4.7 <.001
      Transmission Categoryc
      Injection drug use 2,359 47.1 2,518 50.4 2,625 52.5 2,620 52.5 3.7 1.9 5.6 <.001
      Heterosexual contactd 5,294 55.9 5,689 58.6 6,055 61.0 6,255 61.4 3.2 2.0 4.4 <.001
      Othere 116 53.4 123 58.0 116 56.2 127 61.6 4.1 -3.9 12.7 .327
Total 235,251 53.4 254,821 56.4 273,059 58.8 282,809 59.2 3.5 3.3 3.7 <.001

Abbreviations: HIV= Human Immunodeficiency Virus, EAPC=Estimated Annual Percent Change. Note: The denominator for each characteristic for each year are not presented. aJurisdictions include California, District of Columbia, Hawaii, Iowa, Illinois, Indiana, Louisiana, Maryland, Michigan, Missouri, New Hampshire, New York, North Dakota, South Carolina, Texas, Utah, and West Virginia. bDefined as a viral load result of <200 copies/mL or, if the quantitative value was missing, a test interpretation value of “undetected”, at the time of the most recent viral load test during the outcome year. cData statistically adjusted to account for missing transmission categories. dHeterosexual contact with a person known to have, or to be at high risk for, HIV infection. eIncludes hemophilia, blood transfusion, perinatal exposure and risk factor not reported or not identified.

Back to Article